---
id: bacterial-meningitis-pathogens_084
category: clinical_syndromes
tags: [bacterial-meningitis, S-pneumoniae, N-meningitidis, Listeria-monocytogenes, meningitis-treatment]
deck: Infectious Diseases
created: 2025-11-10
modified: 2025-11-10
---

## Bacterial Meningitis: Specific Pathogens

**Q:** What are the organism-specific features, risk factors, and targeted treatment for the major bacterial meningitis pathogens (S. pneumoniae, N. meningitidis, Listeria monocytogenes)?

**A:**

## 1. STREPTOCOCCUS PNEUMONIAE (Pneumococcus)

**#1 CAUSE of bacterial meningitis in adults** (50-60% of cases)

---

### **Epidemiology:**

**Incidence:**
- **~0.8-1.5 cases per 100,000** (post-PCV13 era - decreased from ~2-3/100,000)
- **Mortality: 20-30%** (highest among bacterial meningitis)

**Risk Factors:**
- **Age:** Infants, elderly (>65 years)
- **Asplenia** (functional or anatomic)
- **CSF leak** (basilar skull fracture, post-neurosurgery)
- **Cochlear implants**
- **Chronic medical conditions:** Diabetes, alcoholism, liver disease, renal failure
- **Immunosuppression:** HIV, complement deficiency, hypogammaglobulinemia

---

### **Clinical Features:**

**Presentation:**
- **Acute onset** (hours to 1-2 days)
- **Severe illness:** High fever, altered mental status
- **Complications:**
  - **Neurologic sequelae** (30-50%): Hearing loss, cognitive impairment, seizures
  - **Subdural empyema, brain abscess** (5-10%)
  - **Septic shock** (20%)

**Key Point:** **S. pneumoniae = highest mortality (20-30%) and highest rate of neurologic sequelae**

---

### **Diagnosis:**

**CSF Findings:**
- **WBC:** 1,000-10,000 cells/μL (PMN predominance >80%)
- **Glucose:** <40 mg/dL (often <20 mg/dL)
- **Protein:** >200 mg/dL
- **Gram stain:** **Gram-positive diplococci** (lancet-shaped, in pairs)
  - **Sensitivity:** 90% (if >10^5 CFU/mL)

**Culture:**
- **Blood cultures positive:** 50-80%
- **CSF culture positive:** 70-90%

---

### **Antimicrobial Resistance:**

**Penicillin Resistance:**
- **Penicillin-susceptible (MIC <0.06 μg/mL):** ~50-60% of isolates
- **Penicillin-intermediate (MIC 0.12-1 μg/mL):** ~25-30%
- **Penicillin-resistant (MIC ≥2 μg/mL):** ~15-25%

**Ceftriaxone Resistance:**
- **Ceftriaxone-resistant (MIC ≥2 μg/mL):** ~5-10% (increasing)

**Key Point:** **Vancomycin + ceftriaxone required empirically** (until susceptibilities known)

---

### **Treatment:**

**Empiric (Until Susceptibilities Known):**

| **Agent** | **Dosing** |
|-----------|------------|
| **Vancomycin** | 15-20 mg/kg IV q8-12h (target trough 15-20 μg/mL) |
| **PLUS** | |
| **Ceftriaxone** | 2g IV q12h |
| **PLUS** | |
| **Dexamethasone** | 10 mg IV q6h x 4 days (BEFORE/WITH first antibiotic dose) |

---

**Directed Therapy (After Susceptibilities):**

| **Susceptibility** | **Regimen** | **Duration** |
|--------------------|-------------|--------------|
| **Penicillin-susceptible** (MIC <0.06 μg/mL) | **Penicillin G** 24 million units/day IV continuous OR divided q4h<br>OR **Ceftriaxone** 2g IV q12h | **10-14 days** |
| **Penicillin-intermediate** (MIC 0.12-1 μg/mL) | **Ceftriaxone** 2g IV q12h | **10-14 days** |
| **Penicillin-resistant** (MIC ≥2 μg/mL) | **Vancomycin** + **Ceftriaxone** 2g IV q12h | **10-14 days** |
| **Ceftriaxone-resistant** (MIC ≥2 μg/mL) | **Vancomycin** + **Rifampin** 600 mg IV/PO q24h<br>OR **Meropenem** 2g IV q8h | **10-14 days** |

**Key Point:** **Continue vancomycin + ceftriaxone** if penicillin-resistant OR ceftriaxone MIC >0.5 μg/mL

---

### **Adjunctive Dexamethasone:**

**Benefit:**
- **Reduces mortality** (RR 0.5 in S. pneumoniae meningitis)
- **Reduces neurologic sequelae** (hearing loss 50% → 25%)

**Dosing:**
- **Dexamethasone** 10 mg IV q6h x **4 days**
- **MUST give BEFORE or WITH first antibiotic dose**

**Key Point:** **Greatest benefit in S. pneumoniae meningitis** (vs other pathogens)

---

### **Complications:**

**Neurologic Sequelae (30-50%):**
- **Hearing loss** (#1 complication - 20-30%)
- **Cognitive impairment**
- **Seizures** (10-20%)
- **Hydrocephalus**
- **Stroke** (infarction, vasculitis)

**Prevention:**
- **Dexamethasone** reduces hearing loss
- **Audiometry** at discharge (screen for hearing loss)

---

### **Prevention:**

**Vaccination:**
- **PCV20 (Prevnar 20):** Conjugate vaccine (20 serotypes) - ≥65 years, immunocompromise
- **PPSV23 (Pneumovax 23):** Polysaccharide vaccine (23 serotypes) - adjunct in high-risk

**Asplenia:**
- **Prophylactic penicillin** VK 250-500 mg PO BID (lifelong or until vaccination complete)

---

## 2. NEISSERIA MENINGITIDIS (Meningococcus)

**#2 CAUSE of bacterial meningitis** (10-35% of cases)

---

### **Epidemiology:**

**Serogroups:**
- **Most common in US:** B, C, Y
- **Africa (meningitis belt):** A, W, X
- **Worldwide:** A, B, C, W, Y

**Incidence:**
- **~0.15 cases per 100,000** (post-vaccination)
- **Mortality: 10-15%** (with treatment; 50% without)

**Risk Factors:**
- **Age:** Infants (<1 year), adolescents/young adults (15-24 years)
- **Close quarters:** College dormitories, military barracks, Hajj pilgrimage
- **Complement deficiency:** C5-C9 (terminal complement deficiency)
- **Asplenia**
- **Eculizumab (Soliris)** therapy (C5 inhibitor)

---

### **Clinical Features:**

**Presentation:**
- **Hyperacute onset** (hours)
- **Rapid progression** to shock, coma
- **Petechial/purpuric rash** (40-60% of cases) - **CLASSIC**
  - Lesions enlarge rapidly
  - **If purpura + hypotension = meningococcemia + shock (Waterhouse-Friderichsen syndrome)**

**Waterhouse-Friderichsen Syndrome:**
- **Meningococcemia + adrenal hemorrhage**
- **Fulminant septic shock**
- **DIC, purpura fulminans**
- **Mortality: 40-50%**

**Key Point:** **Petechial/purpuric rash = suspect N. meningitidis** (give ceftriaxone immediately)

---

### **Diagnosis:**

**CSF Findings:**
- **WBC:** 1,000-10,000 cells/μL (PMN predominance)
- **Glucose:** <40 mg/dL
- **Protein:** 100-500 mg/dL
- **Gram stain:** **Gram-negative diplococci** (kidney bean-shaped)
  - **Sensitivity:** 60-80% (lower than S. pneumoniae)

**Culture:**
- **Blood cultures positive:** 50-75%
- **CSF culture positive:** 70-85%
- **Petechial skin lesion biopsy:** Can culture/Gram stain

**PCR:**
- **Meningococcal PCR** from blood/CSF (high sensitivity, especially if antibiotics given)

---

### **Treatment:**

**Empiric:**

| **Agent** | **Dosing** |
|-----------|------------|
| **Ceftriaxone** | 2g IV q12h |
| **OR Cefotaxime** | 2g IV q4-6h |
| **OR Penicillin G** | 24 million units/day IV (if penicillin-susceptible) |

**Duration:** **5-7 days** (shortest duration among bacterial meningitis)

---

**Directed Therapy:**

| **Agent** | **Dosing** | **Duration** |
|-----------|------------|--------------|
| **Penicillin G** (if susceptible) | 24 million units/day IV continuous OR divided q4h | **5-7 days** |
| **Ceftriaxone** | 2g IV q12h | **5-7 days** |
| **Chloramphenicol** (penicillin allergy) | 1g IV q6h | **5-7 days** |

**Key Point:** **N. meningitidis = shortest treatment duration (5-7 days)**

---

### **Adjunctive Dexamethasone:**

**Controversial:**
- **Less clear benefit** than in S. pneumoniae
- **May consider** in severe cases, but **NOT routinely recommended**

---

### **Chemoprophylaxis for Close Contacts:**

**Indication:**
- **Close contacts** (household, daycare, direct contact with oral secretions, healthcare workers exposed to secretions)

**Regimens:**

| **Agent** | **Dosing** |
|-----------|------------|
| **Rifampin** (preferred if available) | 600 mg PO BID x 2 days (4 doses) |
| **Ciprofloxacin** | 500 mg PO x 1 dose |
| **Ceftriaxone** | 250 mg IM x 1 dose (500 mg if pregnant) |
| **Azithromycin** (alternative) | 500 mg PO x 1 dose |

**Timing:**
- **Give ASAP** (within 24 hours of index case diagnosis)

**Key Point:** **Prophylaxis for close contacts MANDATORY** (N. meningitidis highly contagious)

---

### **Prevention:**

**Vaccination:**

**MenACWY (Conjugate Vaccine):**
- **Routine:** Age 11-12 years (booster at 16 years)
- **High-risk:** Asplenia, complement deficiency, college students, military, travelers to endemic areas

**MenB (Serogroup B Vaccine):**
- **Outbreaks** (college campuses)
- **High-risk:** Asplenia, complement deficiency, eculizumab therapy

**Key Point:** **MenACWY + MenB for asplenia, complement deficiency, eculizumab**

---

## 3. LISTERIA MONOCYTOGENES

**Incidence:** 5-10% of bacterial meningitis (but higher in specific populations)

---

### **Epidemiology:**

**Risk Factors:**
- **Age >50 years** (↑ risk)
- **Pregnancy** (pregnancy-associated listeriosis)
- **Immunosuppression:**
  - Corticosteroids, TNF-α inhibitors
  - Solid organ transplant
  - Hematologic malignancy (lymphoma, leukemia)
  - Chronic kidney disease
- **Alcoholism, cirrhosis**
- **Diabetes**

**Transmission:**
- **Foodborne:** Unpasteurized dairy (soft cheeses), deli meats, hot dogs, smoked seafood

**Key Point:** **Think Listeria if age >50, immunocompromised, or pregnant**

---

### **Clinical Features:**

**Presentation:**
- **Subacute onset** (days to weeks) - more indolent than S. pneumoniae
- **Meningoencephalitis** (meningitis + encephalitis features)
  - **Rhombencephalitis** (brainstem involvement) - classic for Listeria
  - **Cranial nerve palsies** (especially CN VI, VII)
  - **Ataxia, tremor, seizures**

**Key Point:** **Listeria = meningoencephalitis + brainstem involvement (rhombencephalitis)**

---

### **Diagnosis:**

**CSF Findings:**
- **WBC:** 100-1,000 cells/μL (often LOWER than other bacterial meningitis)
- **Differential:** **Variable** (PMN or lymphocyte predominance)
  - 30-40% have lymphocyte predominance (mimics viral/TB meningitis)
- **Glucose:** <40 mg/dL (but may be normal in 30%)
- **Protein:** 100-500 mg/dL
- **Gram stain:** **Gram-positive bacilli** (small, "tumbling" motility)
  - **Sensitivity:** Only 30-40% (often missed on Gram stain)

**Culture:**
- **Blood cultures positive:** 60-70%
- **CSF culture positive:** 70-80%
- **Grows at 4°C** ("cold enrichment" method)

**Key Point:** **Listeria CSF may mimic viral/TB meningitis** (lymphocyte predominance, lower WBC)

---

### **Treatment:**

**Empiric (If Risk Factors Present):**

| **Agent** | **Dosing** |
|-----------|------------|
| **Ampicillin** | 2g IV q4h (12g/day) |
| **PLUS** | |
| **Gentamicin** | 5-7 mg/kg IV q24h (synergy) |

**Duration:** **≥21 days** (minimum 21 days, longer if immunocompromised)

---

**Alternative (Penicillin Allergy):**

| **Agent** | **Dosing** | **Duration** |
|-----------|------------|--------------|
| **TMP-SMX** | 10-20 mg/kg/day (TMP component) IV divided q6-8h | **≥21 days** |
| **OR Meropenem** | 2g IV q8h | **≥21 days** |

**Key Point:** **Cephalosporins do NOT cover Listeria** (must use ampicillin, TMP-SMX, or meropenem)

---

### **Adjunctive Gentamicin:**

**Indication:**
- **Add gentamicin x 7-10 days** (synergy with ampicillin)

**Rationale:**
- **In vitro synergy** (but unclear clinical benefit)

---

### **Prognosis:**

**Mortality:** 20-30% (similar to S. pneumoniae)

**Neurologic Sequelae:** 30-50%

---

## COMPARISON: S. PNEUMONIAE VS. N. MENINGITIDIS VS. LISTERIA

| **Feature** | **S. pneumoniae** | **N. meningitidis** | **Listeria monocytogenes** |
|-------------|-------------------|---------------------|----------------------------|
| **Frequency** | #1 (50-60%) | #2 (10-35%) | 5-10% |
| **Age** | Infants, elderly | Infants, adolescents/young adults | >50 years |
| **Risk Factors** | Asplenia, CSF leak, cochlear implant | Close quarters, complement deficiency | Immunosuppressed, pregnancy, age >50 |
| **Onset** | Acute (hours-days) | Hyperacute (hours) | Subacute (days-weeks) |
| **Rash** | None | **Petechial/purpuric** (40-60%) | None |
| **CSF WBC** | 1,000-10,000 | 1,000-10,000 | 100-1,000 (lower) |
| **CSF Differential** | PMN predominance | PMN predominance | Variable (30-40% lymph predominance) |
| **Gram Stain** | **Gram-positive diplococci** | **Gram-negative diplococci** | **Gram-positive bacilli** (low sensitivity 30-40%) |
| **Treatment** | Vancomycin + ceftriaxone | Ceftriaxone (or penicillin G) | **Ampicillin + gentamicin** |
| **Cephalosporin Coverage** | ✅ Yes | ✅ Yes | ❌ **NO** (must use ampicillin) |
| **Duration** | **10-14 days** | **5-7 days** | **≥21 days** |
| **Dexamethasone** | ✅ **YES** (clear benefit) | ❓ Controversial | ❌ No benefit |
| **Mortality** | **20-30%** (highest) | 10-15% | 20-30% |
| **Prophylaxis** | ❌ No | ✅ **YES** (rifampin, cipro) | ❌ No |

---

**Mnemonic: "PeN for Pneumococcus, CeN for Meningococcus, AmP for Listeria"**
- **P**enicillin G (or ceftriaxone) for **P**neuMococcus
- **C**eftriaxone for meni**N**gococcus
- **A**mpicillin for Listeria

**Mnemonic: "Listeria = Lymphocytes + >50 years + NO Cephalosporin"**
- **L**ymphocytes (may be predominant in CSF - 30-40%)
- **>50** years old
- **NO** cephalosporin coverage (must use ampicillin)

**Mnemonic: "Meningococcus = Minutes to Purpura"**
- **M**eningococcus
- **M**inutes (hyperacute onset)
- **P**urpura (petechial/purpuric rash)

**Clinical Pearls:**
- **S. pneumoniae = #1 cause** (50-60%), highest mortality (20-30%), highest neurologic sequelae
- **Dexamethasone benefit GREATEST in S. pneumoniae** (reduces mortality, hearing loss)
- **N. meningitidis = petechial/purpuric rash** (40-60%) - hyperacute onset
- **Waterhouse-Friderichsen = meningococcemia + adrenal hemorrhage** (fulminant shock, DIC)
- **N. meningitidis = shortest treatment (5-7 days)**
- **Chemoprophylaxis MANDATORY for meningococcal contacts** (rifampin, cipro, ceftriaxone)
- **Listeria = age >50, immunocompromised, pregnancy**
- **Listeria = rhombencephalitis** (brainstem involvement)
- **Listeria CSF may mimic viral/TB** (lymphocyte predominance 30-40%, lower WBC)
- **Cephalosporins do NOT cover Listeria** (must use ampicillin, TMP-SMX, or meropenem)
- **Listeria = longest treatment (≥21 days)**
- **Ampicillin + gentamicin for Listeria** (synergy)
- **Hearing loss = #1 S. pneumoniae complication** (20-30%) - screen with audiometry

**Media:** None

**Sources:** [IDSA 2004 - Bacterial Meningitis Guidelines], [Lancet 2021 - Pneumococcal meningitis], [NEJM 2022 - Meningococcal disease], [Clinical Infectious Diseases 2023 - Listeria meningitis], [CDC 2024 - Meningococcal prophylaxis], [European Society of Clinical Microbiology 2024 - Bacterial meningitis update]
